You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
OncoHost will use the funding to finance clinical trials, open a US location, and prepare to launch its proteomics platform called Prophet.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.
Several Treponema sublineages cropped up after a large antibiotic campaign, though sequence data suggests resistance may have arisen only once.
The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.
The DeepChek-HIV assays are designed for settings running either Sanger sequencing or next-generation sequencing workflows, according to the company.
In PLOS this week: sequencing-based way to uncover drug resistance in tuberculosis bacteria, genetic population structure of mosquito vectors, and more.
A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.
Exposure to DNA-damaging cancer treatments affects mutational signatures found in advanced and metastatic cancers, with alterations possibly indicating drug resistance.
The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.
The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.